269 related articles for article (PubMed ID: 24958721)
1. Type II fatty acid synthesis is essential for the replication of Chlamydia trachomatis.
Yao J; Abdelrahman YM; Robertson RM; Cox JV; Belland RJ; White SW; Rock CO
J Biol Chem; 2014 Aug; 289(32):22365-76. PubMed ID: 24958721
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targets in Chlamydial Fatty Acid and Phospholipid Synthesis.
Yao J; Rock CO
Front Microbiol; 2018; 9():2291. PubMed ID: 30319589
[No Abstract] [Full Text] [Related]
3. Enoyl-Acyl Carrier Protein Reductase I (FabI) Is Essential for the Intracellular Growth of Listeria monocytogenes.
Yao J; Ericson ME; Frank MW; Rock CO
Infect Immun; 2016 Dec; 84(12):3597-3607. PubMed ID: 27736774
[TBL] [Abstract][Full Text] [Related]
4. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).
Yao J; Maxwell JB; Rock CO
J Biol Chem; 2013 Dec; 288(51):36261-71. PubMed ID: 24189061
[TBL] [Abstract][Full Text] [Related]
5. Activation of Exogenous Fatty Acids to Acyl-Acyl Carrier Protein Cannot Bypass FabI Inhibition in Neisseria.
Yao J; Bruhn DF; Frank MW; Lee RE; Rock CO
J Biol Chem; 2016 Jan; 291(1):171-81. PubMed ID: 26567338
[TBL] [Abstract][Full Text] [Related]
6. Ternary complex formation of AFN-1252 with Acinetobacter baumannii FabI and NADH: Crystallographic and biochemical studies.
Rao NK; Nataraj V; Ravi M; Panchariya L; Palai K; Talapati SR; Lakshminarasimhan A; Ramachandra M; Antony T
Chem Biol Drug Des; 2020 Aug; 96(2):704-713. PubMed ID: 32227402
[TBL] [Abstract][Full Text] [Related]
7. Chlamydia trachomatis Scavenges Host Fatty Acids for Phospholipid Synthesis via an Acyl-Acyl Carrier Protein Synthetase.
Yao J; Dodson VJ; Frank MW; Rock CO
J Biol Chem; 2015 Sep; 290(36):22163-73. PubMed ID: 26195634
[TBL] [Abstract][Full Text] [Related]
8. AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity.
Rao KN; Lakshminarasimhan A; Joseph S; Lekshmi SU; Lau MS; Takhi M; Sreenivas K; Nathan S; Yusof R; Abd Rahman N; Ramachandra M; Antony T; Subramanya H
Protein Sci; 2015 May; 24(5):832-40. PubMed ID: 25644789
[TBL] [Abstract][Full Text] [Related]
9. N-Acylated Derivatives of Sulfamethoxazole Block Chlamydia Fatty Acid Synthesis and Interact with FabF.
Mojica SA; Salin O; Bastidas RJ; Sunduru N; Hedenström M; Andersson CD; Núñez-Otero C; Engström P; Valdivia RH; Elofsson M; Gylfe Å
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784680
[TBL] [Abstract][Full Text] [Related]
10. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor.
Kaplan N; Albert M; Awrey D; Bardouniotis E; Berman J; Clarke T; Dorsey M; Hafkin B; Ramnauth J; Romanov V; Schmid MB; Thalakada R; Yethon J; Pauls HW
Antimicrob Agents Chemother; 2012 Nov; 56(11):5865-74. PubMed ID: 22948878
[TBL] [Abstract][Full Text] [Related]
11. Escherichia coli enoyl-acyl carrier protein reductase (FabI) supports efficient operation of a functional reversal of β-oxidation cycle.
Vick JE; Clomburg JM; Blankschien MD; Chou A; Kim S; Gonzalez R
Appl Environ Microbiol; 2015 Feb; 81(4):1406-16. PubMed ID: 25527535
[TBL] [Abstract][Full Text] [Related]
12. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli.
Heath RJ; Rock CO
J Biol Chem; 1995 Nov; 270(44):26538-42. PubMed ID: 7592873
[TBL] [Abstract][Full Text] [Related]
13. Sunflower (Helianthus annuus) fatty acid synthase complex: enoyl-[acyl carrier protein]-reductase genes.
González-Thuillier I; Venegas-Calerón M; Garcés R; von Wettstein-Knowles P; Martínez-Force E
Planta; 2015 Jan; 241(1):43-56. PubMed ID: 25204631
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
Lu H; Tonge PJ
Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
[TBL] [Abstract][Full Text] [Related]
15. Ligand- and Structure-Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence.
Kronenberger T; de Oliveira Fernades P; Drumond Franco I; Poso A; Gonçalves Maltarollo V
ChemMedChem; 2019 Dec; 14(23):1995-2004. PubMed ID: 31670463
[TBL] [Abstract][Full Text] [Related]
16. Methyl-branched fatty acids, inhibitors of enoyl-ACP reductase with antibacterial activity from Streptomyces sp. A251.
Zheng CJ; Sohn MJ; Chi SW; Kim WG
J Microbiol Biotechnol; 2010 May; 20(5):875-80. PubMed ID: 20519910
[TBL] [Abstract][Full Text] [Related]
17. Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase.
Massengo-Tiassé RP; Cronan JE
J Biol Chem; 2008 Jan; 283(3):1308-1316. PubMed ID: 18032386
[TBL] [Abstract][Full Text] [Related]
18. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
[TBL] [Abstract][Full Text] [Related]
19. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252.
Parsons JB; Kukula M; Jackson P; Pulse M; Simecka JW; Valtierra D; Weiss WJ; Kaplan N; Rock CO
Antimicrob Agents Chemother; 2013 May; 57(5):2182-90. PubMed ID: 23459481
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the Mitochondrion-Fatty Acid Axis for the Metabolic Reprogramming of Chlamydia trachomatis during Treatment with β-Lactam Antimicrobials.
Shima K; Kaufhold I; Eder T; Käding N; Schmidt N; Ogunsulire IM; Deenen R; Köhrer K; Friedrich D; Isay SE; Grebien F; Klinger M; Richer BC; Günther UL; Deepe GS; Rattei T; Rupp J
mBio; 2021 Mar; 12(2):. PubMed ID: 33785629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
